Eledon Pharmaceuticals: Tegoprubart's Success as a Novel Immunosuppressive Treatment

Eledon Pharmaceuticals' Tegoprubart continues to show promise as an immunosuppressive alternative. The company's focus on developing the drug for various indications, including autoimmune diseases and solid organ transplant rejection, has the potential to disrupt the immunosuppressive drug space. Eledon's efforts to expand the drug's scope have garnered attention, and the company's progress is worth monitoring.